How many Europeans are affected by VKC?

Article

The prevalence of vernal keratoconjunctivitis (VKC) in Europe is 3.2 per 10000 inhabitants, according to a study published in the August 2008 issue of the British Journal of Ophthalmology.

The prevalence of vernal keratoconjunctivitis (VKC) in Europe is 3.2 per 10000 inhabitants, according to a study published in the August 2008 issue of the British Journal of Ophthalmology.

Dominique Brémond-Gignac of the Service d’Ophtalmologie, APHP, Hôpital Robert Debré, Paris, France and colleagues sent a survey to 3003 ophthalmologists across six countries with, cumulatively, 151.9 million inhabitants. The team analyzed the results to extrapolate data for number of VKC cases across the 15 European Union member states (2002). The survey response rate was 29.5% (n=886).

The team estimated 1.16–10.55 inhabitants per 10000 in Western European to be affected by VKC, with 0.30–2.26 per 10000 to be affected by VKC with corneal complications. The prevalence of VKC was found to be lower than expected in most countries questioned, although in Italy the range was 2.4–27.8/10000. However, the ranges for VKC prevalence were 0.7–8.4, 1.2–8.7, 0.6–4.6, 0.7–3.3 and 0.3–1.9 in Finland, Sweden, the Netherlands, France and Norway, respectively. The rate of VKC with corneal complications was 0.4–4.8, 0.3–2.4, 0.2–2.8, 0.2–1.6, 0.3–1.4 and 0.1–1.0 for each of these countries, respectively.

The team concluded that, based on the correlated and extrapolated data, it was most likely that VKC affects 3.2 of every 10000 people in Western Europe, and that the rate of corneal complications with the disease is 0.8 per 10000.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.